Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System

被引:3
作者
Gaujoux-Viala, Cecile [1 ]
Bergmann, Jean-Francois [2 ]
Goguillot, Melanie [3 ]
Melaine, Asma [3 ]
Guerin, Marie [4 ]
Edouard, Alban [4 ]
Benard, Steve [3 ]
Fautrel, Bruno [5 ]
机构
[1] Univ Montpellier, Desbrest Inst Epidemiol & Publ Hlth, CHU Nimes, INSERM,Dept Rheumatol, Montpellier, France
[2] Hop Lariboisiere, AP HP, Paris, France
[3] Steve Consultants, Oullins, France
[4] Galapagos, Puteaux La Defense, France
[5] Sorbonne Univ, Hop La Pitie Salpetriere, AP HP, INSERM,UMRS 1136, Paris, France
来源
RMD OPEN | 2023年 / 9卷 / 04期
关键词
arthritis; rheumatoid; epidemiology; health services research; outcome assessment; health care; RECOMMENDATIONS; GLUCOCORTICOIDS; RISK; PREVALENCE; THERAPY;
D O I
10.1136/rmdopen-2023-003075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but real-world data remain limited. This study aimed to describe real-world RA treatment patterns using data from a French national claims database. Methods This longitudinal study used the French Permanent Representative Sample (Echantillon Generaliste des Beneficiaires) claims database. Patients with RA were identified between 2013 and 2017, with treatment patterns, persistence and adherence described. Results The study population included 2553 patients with RA. Disease-modifying antirheumatic drugs (DMARDs) were prescribed for 1512 (59.2%) patients, of whom 721 (47.6%) did not require discontinuation or treatment switch. There were 377 (24.9%) treatment discontinuations and 114 patients (7.5%) switched to a targeted DMARD (biological and synthetic (Janus kinase inhibitor) DMARDs). Among the 2315 patients with RA in 2017, almost half (n=1102, 47.6%) were not treated with a DMARD. Most (85.7%) received symptomatic treatment (analgesics (81.0%), steroids (49.2%), non-steroidal anti-inflammatory drugs (39.5%)). Of the 1142 treatment initiations identified, 713 (62.4%) were conventional synthetic DMARDs (csDMARDs), with methotrexate being the most frequent (n=553, 48.45%). One-year persistence rates varied between 55.9% (49.2-62.0%) for tumour necrosis factor inhibitors, and 63.4% (59.6-67.0%) for csDMARDs. Treatment adherence, assessed through medication possession ratio, varied between 71.9% and 90.8%, with >= 80% being the adherence cut-off. Almost half of DMARD initiations were associated with long-term (>6 months), high-dose oral steroid use (similar to 7 mg/day prednisone equivalent). Conclusion Despite a diverse therapeutic arsenal, there remains a medical need that is not covered by current RA management, which is frequently compensated for by overprescription of steroids.
引用
收藏
页数:10
相关论文
共 46 条
  • [1] Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients
    Almalag, Haya
    Abouzaid, Hanan H.
    Alnaim, Lamya
    Albaqami, Jawza
    AlShalhoub, Rawan
    Almaghlouth, Ibrahim
    Dessougi, Maha
    Al Harthi, Amal
    Bedaiwi, Mohamed
    Alfi, Eman
    Omair, Mohammed
    [J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2020, 12 : 193 - 202
  • [2] The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review
    Almutairi, Khalid
    Nossent, Johannes
    Preen, David
    Keen, Helen
    Inderjeeth, Charles
    [J]. RHEUMATOLOGY INTERNATIONAL, 2021, 41 (05) : 863 - 877
  • [3] Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis
    Alpay-Kanitez, Nilufer
    Pehlivan, Ozlem
    Omma, Ahmet
    Can-Sandikci, Sevinc
    Girgin, Sinem
    Icacan, Ozan Cemal
    Celik, Selda
    Bes, Cemal
    [J]. MEDICINE, 2020, 99 (16) : E19696
  • [4] High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)
    Amaral, Jessica Martins
    Brito, Maria Jose Menezes
    Kakehasi, Adriana Maria
    [J]. ADVANCES IN RHEUMATOLOGY, 2020, 60 (01)
  • [5] Bannay A., 2014, Adaptation aux donnees du SNIIRAM chaine au PMSIdu score de comorbidite de Charlson et valeur pronostique a unan [Adaptation of the Charlson Comorbidity score to data from the SNIIRAM linked to the PMSI and prognostic value at one year]. Sciences Du Vivant [Q-bio] [Internet]
  • [6] Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis
    Bernard, Marie-Agnes
    Benichou, Jacques
    Blin, Patrick
    Weill, Alain
    Begaud, Bernard
    Abouelfath, Abdelilah
    Moore, Nicholas
    Fourrier-Reglat, Annie
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (06) : 573 - 583
  • [7] Caisse Natrional D'assurance Maladie, Methode de la cartographie des pathologies et des depenses de l'Assurance Maladie
  • [8] Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
    Calasan, Maja Bulatovic
    van den Bosch, Oscar F. C.
    Creemers, Marjonne C. W.
    Custers, Martijn
    Heurkens, Antonius H. M.
    van Woerkom, Jan Maarten
    Wulffraat, Nico M.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2013, 15 (06)
  • [9] Identification of rheumatoid arthritis in German claims data using different algorithms: Validation by cross-sectional patient-reported survey data
    Callhoff, Johanna
    Albrecht, Katinka
    Marschall, Ursula
    Strangfeld, Anja
    Hoffmann, Falk
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (05) : 517 - 525
  • [10] Future therapeutic targets in rheumatoid arthritis?
    Cheung, Tommy Tsang
    McInnes, Iain B.
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2017, 39 (04) : 487 - 500